Condition
Relapsed/Refractory Diffuse Large B Cell Lymphoma
Total Trials
4
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Active Not Recruiting2
Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07621406Phase 2Active Not RecruitingPrimary
Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard Immunochemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07451652Phase 2RecruitingPrimary
Low Dose Epcoritamab Plus GemOx in R/R DLBCL
NCT05335018Phase 2Active Not RecruitingPrimary
GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
NCT03153462UnknownPrimary
Axicabtagene Ciloleucel Expanded Access Study
Showing all 4 trials